Literature DB >> 8750805

Purpura fulminans in severe congenital protein C deficiency: monitoring of treatment with protein C concentrate.

F M Müller1, W Ehrenthal, G Hafner, D Schranz.   

Abstract

UNLABELLED: This report describes the successful use of protein C concentrate to treat severe purpura fulminans in a homozygous protein C-deficient infant for 8 months until oral anticoagulation was initiated. While fresh frozen plasma was previously used in such cases to replace protein C in the acute phase, the availability of a monoclonal antibody purified protein C concentrate now allows specific replacement of protein C, avoiding problems of fluid overload. An occlusive-hydrocolloid bandage proved to be effective in local treatment of skin lesions. D-dimer, fibrin monomer, thrombin-antithrombin complex and prothrombin fragment 1 + 2 were useful markers in monitoring and optimizing protein C replacement therapy.
CONCLUSION: Diagnosis of protein C deficiency should be considered in a newborn with purpura fulminans. Early diagnosis and adequate replacement therapy is life-saving. Today, administration of protein C is the acute as well as long-term therapy of choice.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8750805     DOI: 10.1007/bf02115621

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  43 in total

1.  Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate.

Authors:  M Dreyfus; J F Magny; F Bridey; H P Schwarz; C Planché; M Dehan; G Tchernia
Journal:  N Engl J Med       Date:  1991-11-28       Impact factor: 91.245

2.  Neonatal purpura fulminans associated with homozygous protein S deficiency.

Authors:  C Mahasandana; V Suvatte; R A Marlar; M J Manco-Johnson; L J Jacobson; W E Hathaway
Journal:  Lancet       Date:  1990-01-06       Impact factor: 79.321

3.  Successful treatment of homozygous protein C deficiency by hepatic transplantation.

Authors:  J F Casella; J H Lewis; F A Bontempo; B J Zitelli; H Markel; T E Starzl
Journal:  Lancet       Date:  1988-02-27       Impact factor: 79.321

4.  Reduced axial bone mineral content in patients taking an oral anticoagulant.

Authors:  C E Fiore; C Tamburino; R Foti; D Grimaldi
Journal:  South Med J       Date:  1990-05       Impact factor: 0.954

5.  Detection of protein C deficiency during oral anticoagulant therapy--use of the protein C:factor VII ratio.

Authors:  D W Jones; I J Mackie; M Winter; M Gallimore; S J Machin
Journal:  Blood Coagul Fibrinolysis       Date:  1991-06       Impact factor: 1.276

6.  Replacement therapy with a purified protein C concentrate during initiation of oral anticoagulation in severe protein C congenital deficiency.

Authors:  V De Stefano; S Mastrangelo; H P Schwarz; P Pola; R Flore; B Bizzi; G Leone
Journal:  Thromb Haemost       Date:  1993-08-02       Impact factor: 5.249

7.  Standardization of protein C in plasma: establishment of an international standard.

Authors:  A R Hubbard
Journal:  Thromb Haemost       Date:  1988-06-16       Impact factor: 5.249

8.  Maturation of the hemostatic system during childhood.

Authors:  M Andrew; P Vegh; M Johnston; J Bowker; F Ofosu; L Mitchell
Journal:  Blood       Date:  1992-10-15       Impact factor: 22.113

9.  Report on the diagnosis and treatment of homozygous protein C deficiency. Report of the Working Party on Homozygous Protein C Deficiency of the ICTH-Subcommittee on Protein C and Protein S.

Authors:  R A Marlar; R R Montgomery; A W Broekmans
Journal:  Thromb Haemost       Date:  1989-06-30       Impact factor: 5.249

10.  Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate.

Authors:  W Schramm; M Spannagl; K A Bauer; R D Rosenberg; B Birkner; Y Linnau; H P Schwarz
Journal:  Arch Dermatol       Date:  1993-06
View more
  6 in total

Review 1.  Inherited defects of the protein C anticoagulant system in childhood thrombo-embolism.

Authors:  U Nowak-Göttl; K Auberger; U Göbel; W Kreuz; R Schneppenheim; H Vielhaber; W Zenz; B Zieger
Journal:  Eur J Pediatr       Date:  1996-11       Impact factor: 3.183

2.  Mice with a severe deficiency in protein C display prothrombotic and proinflammatory phenotypes and compromised maternal reproductive capabilities.

Authors:  Angelina J Lay; Zhong Liang; Elliot D Rosen; Francis J Castellino
Journal:  J Clin Invest       Date:  2005-05-05       Impact factor: 14.808

3.  Use of human protein C concentrates in the treatment of patients with severe congenital protein C deficiency.

Authors:  Sabine Kroiss; Manuela Albisetti
Journal:  Biologics       Date:  2010-03-24

4.  Neonatal thrombosis.

Authors:  R Saxena; M Kannan; V P Choudhry
Journal:  Indian J Pediatr       Date:  2003-11       Impact factor: 1.967

5.  Therapeutic levels of human protein C in rats after retroviral vector-mediated hepatic gene therapy.

Authors:  S R Cai; S C Kennedy; W M Bowling; M W Flye; K P Ponder
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

6.  Severe congenital protein C deficiency: the use of protein C concentrates (human) as replacement therapy for life-threatening blood-clotting complications.

Authors:  Paul N Knoebl
Journal:  Biologics       Date:  2008-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.